Athersys grows into ortho market with RTI deal
This article was originally published in Clinica
Cell therapy firm Athersys has entered the orthopaedics industry after licensing its multipoint adult progenitor cell (MAPC) technology to RTI Biologics. The licence will allow RTI (Alachua, Florida) to develop biologic implants for orthopaedic applications, which it aims to make available to orthopaedic surgeries in the first half of 2012. Athersys currently develops stem cell technologies, such as its MultiStem product, for the treatment of certain cardiovascular, central nervous system-related, inflammatory and immune system disorders. Under the terms of the deal, Cleveland, Ohio-based Athersys will receive a $3m fee and will gain up to $37.5m in potential commercialisation milestones and cumulative revenue achievements.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals